Acquisitions, Senior Level Promotions, Public Offering, and Drug Approvals - Research Reports on Acorda, Alexion, Envision, Lilly and Avanir

NEW YORK, September 29, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Acorda Therapeutics, Inc. (NASDAQ: ACOR), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Envision Healthcare Holdings, Inc. (NYSE: EVHC), Eli Lilly and Company (NYSE: LLY) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6820-100free.

--
Acorda Therapeutics, Inc. Research Reports
On September 24, 2014, Acorda Therapeutics, Inc. (Acorda) announced that it has entered into an agreement to acquire privately-held biopharmaceutical firm Civitas Therapeutics for $525 million in cash. The acquisition will give Acorda worldwide rights to CVT-301 -- a Phase III treatment candidate for episodes of Parkinson's disease, and Civitas' proprietary ARCUS pulmonary delivery technology and manufacturing facility in Chelsea, Massachusetts. Following the announcement, shares of Acorda closed with a gain of 28.18% at $37.62. Commenting on the acquisition, Acorda's President and CEO, Ron Cohen, M.D. said, "This acquisition marks a great day for Acorda and Civitas. Both companies share a passion for developing novel therapies that can restore function to people with neurological diseases." The acquisition is expected to be completed in the Q4 2014. The full research reports on Acorda are available to download free of charge at:

http://www.analystsreview.com/Sep-29-2014/ACOR/report.pdf

--
Alexion Pharmaceuticals, Inc. Research Reports
On September 17, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced a series of senior-level promotions and a new hiring, aimed at strengthening its Executive Leadership Team. Alexion said that David Hallal, who previously served as the Executive Vice President and Chief Commercial Officer, has been promoted to a newly created position of Chief Operating Officer and has been appointed to Alexion's Board of Directors. Clare Carmichael has been promoted to Executive Vice President and Chief Human Resources Officer (CHRO) from her previous position of Senior Vice President and CHRO. John Moriarty, J.D. has been elevated to the post of Executive Vice President and General Counsel from his previous position of Senior Vice President and General Counsel. Additionally, the Company has hired Edward Miller, J.D. for the newly created position of Senior Vice President and Chief Compliance Officer. All four executives will report directly to Alexion's CEO Leonard Bell, M.D. The full research reports on Alexion are available to download free of charge at:

http://www.analystsreview.com/Sep-29-2014/ALXN/report.pdf

--
Envision Healthcare Holdings, Inc. Research Reports
On September 23, 2014, Envision Healthcare Holdings, Inc. (Envision) announced the sale of an aggregate of 17.5 million shares of the Company's common stock by investment funds associated with Clayton, Dubilier & Rice, LLC, and certain executive officers and directors of the Company (Selling Stockholders) to Citigroup as the sole underwriter in the registered public offering of those shares. Envision clarified that all the net proceeds from this offering will go to selling shareholders. No shares are being sold by the Company. On September 24, 2014, shares of Envision fell 4.39% to close at $34.22. The full research reports on Envision are available to download free of charge at:

http://www.analystsreview.com/Sep-29-2014/EVHC/report.pdf

--
Eli Lilly and Company Research Reports
On September 18, 2014, Eli Lilly and Company (Lilly) announced that the U.S. Food and Drug Administration (FDA) has approved Trulicity (dulaglutide) - the Company's latest treatment option for adults with type II diabetes. Lilly said that Trulicity 0.75 mg and 1.5 mg single-dose pens will be made available for adults in the U.S. later this year. "We are delighted with the approval of Trulicity. Lilly now has treatment options in several classes of diabetes medications: orals, GLPs and insulin," said Enrique Conterno, President, Lilly Diabetes. "Trulicity will help grow the GLP-1 receptor agonist class as a new choice for adults with type 2 diabetes," Conterno added. The full research reports on Lilly are available to download free of charge at:

http://www.analystsreview.com/Sep-29-2014/LLY/report.pdf

--
Avanir Pharmaceuticals, Inc. Research Reports
On September 23, 2014, Avanir Pharmaceuticals, Inc. (Avanir) announced the pricing of an underwritten public offering of 18.2 million shares of its common stock at a price to the public of $11.00 per share, before underwriting discounts. In addition, Avanir has granted the underwriters a 30-day option to purchase up to an additional 2.73 million shares of its common stock in connection with the offering. Avanir intends to use the net proceeds for general corporate purposes, which include funding NUEDEXTA commercial activities, funding ongoing and future clinical trials, funding the commercial launch of AVP-825, if approved, and for general and administrative expenses. Avanir said that it may also utilize a portion of the net proceeds to pay off debt and/or acquire complementary businesses, products and technologies. The full research reports on Avanir are available to download free of charge at:

http://www.analystsreview.com/Sep-29-2014/AVNR/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review